Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.32 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.32 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.31 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13272404 | 0.79 | — | — | |
| SCHEMBL5540868 | 0.78 | PIM1 (0.32) | PIM1PIM3 | |
| SCHEMBL4405135 | 0.76 | PDGFRB (0.53) | PDGFRBFGFR1KDRZAP70 | |
| SCHEMBL15329737 | 0.76 | APOBEC3G (0.33) | PDGFRBFGFR1KDRZAP70 | |
| SCHEMBL25021307 | 0.75 | — | — | |
| SCHEMBL2673489 | 0.75 | — | — | |
| SCHEMBL9539293 | 0.72 | IGF1R (0.32) | PDGFRBFGFR1KDR | |
| SCHEMBL6060895 | 0.72 | — | — | |
| SCHEMBL9423160 | 0.72 | GRIN2D (0.31) | KMT2A | |
| SCHEMBL14125886 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4269387-A1 | PYRROLINONE COMPOUND AND SYNTHESIS METHOD THEREFOR | Poseidon Pharmaceutical Co., Ltd. (CN) | 2023-11-01 | — | — | EP | disclosed |
| US-20230322671-A1 | PYRROLINONE COMPOUND AND METHOD FOR PREPARING THE SAME | WUHAN JIANMIN DAPENG PHARMACEUTICAL CO., LTD. (CN) | 2023-10-12 | — | — | US | disclosed |
| US-20230322671-A1 | PYRROLINONE COMPOUND AND METHOD FOR PREPARING THE SAME | WUHAN JIANMIN DAPENG PHARMACEUTICAL CO., LTD. (CN) | 2023-10-12 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322671-A1 | PYRROLINONE COMPOUND AND METHOD FOR PREPARING THE SAME | C1S, C5, SULT1A1 | ALDH1A1 706/4885POLB 2982/4885KMT2A 4047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.